araag2/HINT huggingface dataset:
Clinical trial NCT00324974 (phase 3, status: completed)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: lansoprazole microgranules suspension, placebo
SMILES: CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  At least 7 days post-surgery at the time of Screening (Study Visit 1) with no
             anticipated need for surgery during the study.

          -  Experiencing symptoms of gastroesophageal reflux disease (regurgitation, vomiting or
             "spitting up," fussing/irritability, feeding refusal, crying during feeding, arching
             back, poor weight gain, or extraesophageal manifestations) or endoscopy proven reflux
             disease.

          -  Must continue to have reflux symptoms during the Pretreatment Period despite reducing
             or eliminating exposure to tobacco smoke, using one positioning and feeding strategy
             the last 7 days as documented in the Daily Diary.

          -  The infant exhibited crying, fussing, or irritability during or within 1 hour of
             feeding in >25% of all feedings during the last 4 days of the Pretreatment Period as
             documented in the Daily Diary.

        Exclusion Criteria:

          -  Body weight <2.0 kilogram at Dosing Day 1 of the Double-Blind Treatment Period.

          -  Unstable, congenital or acquired, clinically significant disease of any major organ
             system (cardiovascular, respiratory, renal, hepatic, metabolic, etc.), including
             suspected and/or documented culture-proven sepsis.

          -  Coexisting esophageal disease (e.g., eosinophilic esophagitis, viral, bacterial or
             fungal infection) or caustic or physiochemical trauma to the esophagus.

          -  Any congenital anomaly of the upper gastric intestinal tract that might interfere with
             gastrointestinal motility, pH, absorption, or active or known history of necrotizing
             enterocolitis that has been surgically corrected.

          -  Use of a proton pump inhibitor within 30 days prior to Dosing Day 1.

          -  Use of H2 Blockers (i.e. Zantac) within 7 days prior to Dosing Day 1.

          -  Allergy to proton pump inhibitors (i.e. Prilosec, Prevacid).

          -  Use of prokinetics (e.g., metoclopramide) unless on a stable dose for at least 3 days
             prior to entering the Pretreatment Period.

          -  Unable to obtain stable drug levels after continuous treatment with required drugs
             including theophylline derivatives, digoxin, phenytoin, phenobarbital, or
             carbamazepine within the 7 days prior to Dosing Day 1.

          -  Clinically Significant abnormalities in clinical laboratory values.
Clinical trial NCT01039688 (phase 3, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cp-690,550, cp-690,550, disease-modifying antirheumatic drug
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults with moderate to severe RA (Rheumatoid Arthritis) who have not been treated
             with methotrexate.

          -  Diagnosis of RA based on the American College of Rheumatology 1987 revised criteria.

          -  Active disease as defined by both >=6 tender or painful joints on motion and >= 6
             joints swollen; and either an erythrocyte sedimentation rate (ESR) > 28 mm or a
             C-reactive protein (CRP) concentration > 7 mg/dL

        Exclusion Criteria:

          -  Blood dyscrasias including confirmed: Hemoglobin <9 g/dL or Hematocrit <30%; White
             blood cell count <3.0 x 109/L; Absolute neutrophil count <1.2 x 109/L; Platelet count
             <100 x 109/L

          -  History of any other rheumatic autoimmune disease other than Sjogren's syndrome

          -  No malignancy or history of malignancy

          -  History of infection requiring hospitalization, parenteral antimicrobial therapy, or
             as otherwise judged clinically significant by the investigator, within the 6 months
             prior to the first dose of study drug

          -  No chronic liver disease, recent or active hepatitis or other contraindication to
             methotrexate therapy
Clinical trial NCT01156142 (phase 3, status: completed)
Conditions: head and neck cancer, mucositis, oral complications of radiation therapy, pain
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, J34.81, K92.81, K12.30, K12.39, K12.33, N76.81, K12.31, A36.89, B01.89, B02.9, B05.89, B06.89, B26.89, K94.30, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: doxepin hydrochloride
SMILES: CN(C)CCC=C1C2=CC=CC=C2COC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          1. ≥ 18 years of age

          2. Histologic proof of malignancy currently undergoing a course of RT (with or without
             chemotherapy) to a dose of ≥ 5000 cGy using 1.60 to 2.20 Gy per fraction. Note: At
             least one third of the oral cavity mucosa must be included in the radiation therapy
             fields.

          3. ≥ 4 oral pain felt to be related to mucositis for which the patient wants relief as
             measured by the Numeric Measure of Oral Pain. Note: An oral exam confirming the
             presence of mucositis should be performed by the enrolling clinician in addition to
             patient feedback.

          4. Ability to complete questionnaire(s) independently or with assistance

          5. ECOG Performance Status 0, 1 or 2.

          6. Provide informed written consent.

          7. Willingness to return to enrolling institution for follow-up.

        Exclusion Criteria:

          1. Known allergy to doxepin, tricyclic antidepressants, or any known component of the
             drug formulation

          2. Use of a tricyclic antidepressant or monoamine oxidase inhibitor within the 2 weeks
             prior to registration

          3. Current untreated or unresolved oral candidiasis or oral HSV infection

          4. Current untreated narrow angle glaucoma

          5. Current untreated urinary retention ≤ 6 weeks prior to registration

          6. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          7. Any of the following because this study involves a study agent whose genotoxic,
             mutagenic and teratogenic effects on the developing fetus and newborn are unknown:

               -  Pregnant women

               -  Nursing women

               -  Men or women of childbearing potential who are unwilling to employ adequate
                  contraception
Clinical trial NCT00417079 (phase 3, status: completed)
Conditions: neoplasms, prostatic neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: cabazitaxel (xrp6258) (rpr116258), mitoxantrone, prednisone
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria

          1. Histologically or cytologically confirmed adenocarcinoma of the prostate that is
             refractory to hormone therapy and previously treated with a Taxotere®-containing
             regimen.

          2. Documented progression of disease (demonstrating at least one visceral or soft tissue
             metastatic lesion, including a new lesion). Patients with non-measurable disease must
             have documented rising prostate-specific antigen (PSA) levels or appearance of new
             lesion.

          3. Surgical or hormone-induced castration

          4. Life expectancy > 2 months

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2

        Exclusion criteria

          1. Previous treatment with mitoxantrone

          2. Previous treatment with <225 mg/m^2 cumulative dose of Taxotere (or docetaxel)

          3. Prior radiotherapy to ≥ 40% of bone marrow

          4. Surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to
             enrollment in the study

          5. Other prior malignancy, except for adequately treated superficial basal cell skin
             cancer, or any other cancer from which the patient has been disease-free for less than
             5 years

          6. Known brain or leptomeningeal involvement

          7. Other concurrent serious illness or medical conditions

          8. Inadequate organ function evidenced by unacceptable laboratory results

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
Clinical trial NCT00582114 (phase 3, status: terminated)
Conditions: hemodialysis, hypertension, left ventricular hypertrophy
ICD codes: I95.3, R88.0, Z49.31, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, I47.2, I49.01, I49.02, I49.3, Q21.0, I47.0, I50.1
Drugs: lisinopril, atenolol
SMILES: CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
Reason stopped: 
    stopped by data safety monitoring board
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients on chronic hemodialysis for > 3 mos.

          2. Compliance with hemodialysis treatments as defined by less than one missed dialysis
             per month

          3. Hypertension as diagnosed by ambulatory blood pressure monitoring (ABPM) >135/75 mm Hg
             after participation in the ultrafiltration (UF) Trial, or those on no antihypertensive
             medications but unwilling to do UF Trial.

          4. Presence of LVH on echocardiogram defined as left ventricular mass index (LVMi) >104
             g/m2 in women and >116 g/m2 in men.

          5. Willingness to give informed consent.

        Exclusion criteria:

          1. Vascular event (stroke, myocardial infarction or limb ischemia requiring bypass)
             within previous six months

          2. Noncompliance with hemodialysis treatments

          3. Known drug abuse

          4. Chronic obstructive pulmonary disorder (COPD) requiring home oxygen

          5. Congestive Heart Failure Class III or IV.

          6. Body mass index > 40 kg/m2.

          7. Known contraindication to atenolol (severe heart failure, bradycardia, bronchial
             asthma, intolerance or allergy) or lisinopril (cough, pregnancy, intolerance or
             allergy)
Clinical trial NCT01622231 (phase 3, status: completed)
Conditions: rhinitis
ICD codes: J30.0, J31.0, J30.89, J30.9, A50.05, J30.2, J30.1
Drugs: fluticasone furoate
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Informed Consent

          -  2 to <15 years of age, male or eligible female (females of childbearing potential must
             commit to consistent and correct use of an acceptable method of birth control),
             outpatient

          -  Diagnosis of perennial allergic rhinitis: A positive test response to house dust
             and/or dust mites on serum antigen-specific IgE antibody test at Visit 1. Six months
             or more clinical history of perennial allergic rhinitis. A positive test result on
             nasal eosinophil count at Visit 1/1A.

          -  Either subject's parent/guardian who signed ICF or subject is able to complete
             assessments on the patient diary through the study.

          -  ALT < 2xULN; alkaline phosphatase and bilirubin <= 1.5xULN

          -  Average of 3TNSS is >= 3.0 in the last consecutive 4 days prior to Visit 2.

          -  Completion of the patient diary on >= 3 days of the last consecutive 4 days prior to
             Visit 2

        Exclusion Criteria:

          -  Has a seasonal pollen as an allergen

          -  A nose disorder that could affect the assessment of the study medication or eye or
             nose surgery (within 3 months prior to Visit 1)

          -  Bacterial or viral infection of upper respiratory tract or eye

          -  Concurrent disease/abnormalities: Clinically significant uncontrolled disease

          -  Known hypersensitivity to corticosteroids or any excipients in the investigational
             product

          -  Has recent participation in a study and/or exposure to an investigational study drug
             within 3 months prior to Visit 1

          -  Use of the following medication and/or its combination drug within the specified time:

        Anti-IgE (Within 6 months prior to Visit 1), Immunosuppressive medications or Systemic
        corticosteroids (Within 8 weeks prior to Visit 1), Topical corticosteroids (Within 4 weeks
        prior to Visit 1), Immunotherapy or nonspecific allassotherapy which was initiated,
        discontinued or changed its dose within 4 weeks prior to Visit 1

          -  Affiliation with Investigator's Site: Relative or employee

          -  History of alcohol or drug abuse, children in care or in the opinion of the
             investigator (sub-investigator), inappropriate to be enrolled in the study.

          -  Bacterial or viral infection of upper respiratory tract or eye during the screening
             period.
Clinical trial NCT01516970 (phase 3, status: completed)
Conditions: human immunodeficiency virus (hiv)
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: darunavir/ritonavir (drv/r), lopinavir in fixed combination with ritonavir, zidovudine, nrtis, efavirenz
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Occupational injury and non-occupational exposure with documented human
             immunodeficiency virus (HIV) exposure, or potential for HIV exposure

          -  Indication for HIV postexposure prophylaxis (PEP), as determined by the treating
             physician and/or the investigator

          -  Women must be: postmenopausal (for at least 2 years), surgically sterile, using oral
             contraceptives

          -  Willing to continue HIV PEP for 28 days

        Exclusion Criteria:

          -  Positive HIV rapid test

          -  History of liver or renal insufficiency; significant cardiac, vascular, pulmonary,
             gastro intestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or
             metabolic disturbances

          -  Pregnant or breast-feeding

          -  Any condition that, in the opinion of the investigator, would compromise the
             well-being of the participant or the study or prevent the participant from meeting or
             performing study requirements
Clinical trial NCT01206387 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: desoximetasone spray 0.25%, placebo comparator
SMILES: [H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Male or non-pregnant, non-lactating female 18 years of age or older.

          -  Have a definite clinical diagnosis of stable plaque psoriasis involving ≥ 10% of the
             body surface area (BSA).

          -  Have a combined total lesion severity score (TLSS) of ≥ 7 for the Target Lesion.

          -  Have a plaque elevation score ≥ 3 of (moderate) for the Target Lesion.

          -  The Target Lesion must have an area of at least 5 cm².

          -  Have a Physicians Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at
             baseline for the overall disease severity.

        Exclusion Criteria:

          -  Patient has current diagnosis of other types of psoriasis other than stable plaque
             psoriasis (i.e. acute, guttate, erythrodermic, exfoliative or pustular psoriasis) or
             has psoriasis of any kind of the face or scalp that will require active treatment
             during the study. Nonprescription antipsoriatic shampoos will be allowed during the
             study when applied solely to the scalp.

          -  Patient has a history of psoriasis that has been unresponsive to topical
             corticosteroid therapy.

          -  In the Investigator's opinion, the patient has other dermatological conditions, such
             as atopic or contact dermatitis, that may interfere with the clinical assessments of
             the signs and symptoms of psoriasis.

          -  Patient has a history of allergy or sensitivity to corticosteroids or history of any
             drug hypersensitivity or intolerance which, in the opinion of the Investigator, would
             compromise the safety of the patient or the results of the study.

          -  Patient has been treated within 12 weeks (or five half lives, whichever is less) prior
             to the first dose of study drug with any biological therapies for psoriasis.

          -  Patient has received any systemic steroids within 4 weeks of the first dose of the
             study drug. The use of inhaled or intranasal corticosteroids is acceptable as long as
             usage has been stable for at least 2 weeks prior to the first dose of study drug and
             will be continued during the study.

          -  Patients who have used any topical antipsoriatic agents of any kind or any topical
             corticosteroids for any reason within 2 weeks prior to first use of study drug.
             Nonprescription antipsoriatic shampoos used only on the scalp will be allowed during
             the study.

          -  Receipt of any drug as part of a research study within 30 days prior to first dosing.
Clinical trial NCT00298623 (phase 3, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: xp13512 (gsk1838262)
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with primary RLS, based on the International RLS Study Group Diagnostic
             Criteria.

          -  History of RLS symptoms at least 15 nights in the prior month or, if on treatment,
             this frequency of symptoms before treatment was started;

          -  Documented RLS symptoms for at least 4 of the 7 consecutive evenings/nights during the
             Baseline study period;

          -  Total RLS severity score of 15 or greater on the International Restless Legs Syndrome
             Study Group Rating Scale (IRLS rating scale) at Visit 1 and at Visit 2;

          -  Discontinuation of dopamine agonists and/or gabapentin at least 2 weeks prior to
             Baseline;

          -  Discontinuation of other treatments for RLS (e.g., opioids, benzodiazepines) at least
             2 weeks prior to Baseline;

          -  If female of child-bearing potential, the subject must agree to use clinically
             accepted birth control through completion of the study;

          -  Body Mass Index of 34 or below;

          -  Estimated creatinine clearance of at least 60 mL/min;

        Exclusion Criteria:

          -  A sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of
             RLS;

          -  Neurologic disease or movement disorder (e.g., diabetic neuropathy, Parkinson's
             Disease, Multiple Sclerosis, dyskinesias, and dystonias);

          -  Abnormal laboratory results, electrocardiogram (ECG) or physical findings;

          -  Pregnant or lactating women;

          -  Women of childbearing potential who are not practicing an acceptable method of birth
             control.
Clinical trial NCT00221416 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: aripiprazole
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Male or Females; between the ages of 7 years 0 months to 17 years 12 months

          2. Bipolar I Disorder, mixed or manic episode, psychotic or non-psychotic, according to
             DSM IV criteria.

          3. Score of > 20 on the Y-MRS at baseline.

          4. Ability and willingness to provide assent and informed written consent from at least
             one parent or legal guardian

          5. No current general medical illnesses requiring medication that would effect
             interpretation of study outcomes.

          6. Subjects must have at least normal intelligence.

          7. Female patients of childbearing potential must be using a reliable method of
             contraception, e.g. hormonal contraceptives, Depo-Provera, double-barrier methods
             (e.g. condom and diaphragm, condom and foam, condom and sponge) or abstinence).
             Females of childbearing potential must have a negative serum pregnancy test
             immediately prior to study entry.

          8. Must be able to swallow oral medication (tablets).

        Exclusion Criteria:

          1. A current or lifetime DSM-IV diagnosis of schizophrenia, autistic disorder,
             schizoaffective disorder, pervasive developmental disorder, or obsessive compulsive
             disorder

          2. Known IQ < 70

          3. Patients with high suicide risk defined as any serious suicide attempt that required
             medical intervention or current suicide risk that cannot be safely managed as
             determined by the clinical judgment of the investigator.

          4. Concurrent cognitive behavioral psychotherapy.

          5. Present or past (within 3 months) DSM-IV diagnosis of substance abuse/dependence.

          6. Female patients who are pregnant, trying to become pregnant, nursing an infant, or not
             using a reliable form of contraception.

          7. Bipolar subjects who are currently stable on mood stabilizers or atypical
             neuroleptics.

          8. Patient has failed on a previous adequate course of aripiprazole.

          9. A known hypersensitivity to aripiprazole or to any of its components.

         10. Participated in an investigational drug/device trial within the last 30 days.

         11. Patients with severe renal insufficiency, defined as creatinine clearance <30ml/min.
             by history or by lab findings.

             -
Clinical trial NCT00141323 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: lasofoxifene, lasofoxifene
SMILES: [H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1, [H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

        Postmenopausal at least 5 years; Screening bone mineral density more than or equal to 2.5
        S.D.s below the mean for young adults at the lumbar spine or femoral neck.

        Exclusion Criteria:

        Metabolic bone disease other than osteoporosis; Taking approved medications for
        osteoporosis; Have had a recent osteoporotic fracture (within 1 year) and/or have a bone
        mineral density more than 4.5 S.D.s below the mean for young adults at the lumbar spine or
        femoral neck.